Fig. 2From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancerTornado diagram for deterministic sensitivity analysis. Plot shows the range in incremental cost-effectiveness ratio (ICER) when each variables is tested between at the maximum and the minimum values. Variables to which ICER were not sensitive are not shownBack to article page